An Open-label Phase I Single Dose Escalation Trial of Two Dosing Schedules of BI 831266 Administered Intravenously Over 24 h Continuously in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 23 Dec 2014
At a glance
- Drugs BI 831266 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 14 Jan 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 14 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Aug 2010 Planned end date changed from 1 Aug 2010 to 1 Nov 2010 as reported by ClinicalTrials.gov.